|
|
Expression and clinical significance of DNAJB11 in epithelial ovarian cancer |
YAO Guorong1,3( ),FU Yunfeng1,LI Yanli1,ZHOU Caiyun2,LV Weiguo1,*( ) |
1. Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China 2. Department of Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China 3. Department of Obstetrics and Gynecology, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China |
|
|
Abstract Objective: To study the expression of DNAJB11 protein in epithelial ovarian cancer tissues and its clinical significance. Methods: Immunohistochemistry was used to examine DNAJB11 expressions in 105 tissue specimens of ovarian epithelial carcinoma, 23 normal ovarian tissues, 17 tissues of benign tumor, and 13 tissues of of borderline tumor. The correlations between protein expression and clinicopathological factors were analyzed by Chi square test.The correlations between protein expression and survival were analyzed by Kaplan-Meier and Cox regression. Results: Positive expression of DNAJB11 protein was observed in 0.0% in normal ovary and benign tumor, 7.69% in borderline tumor, and 78.10% in epithelial ovarian cancer, respectively. Positive expression of DNAJB11 protein was significantly higher than the rest of the ovarian tissues and normal ovarian tissues (P<0.001).Higher expression of DNAJB11 was more prevalent in tissues from patients with advanced FIGO stages, high serum CA125, poor histological differentiation, and serous cancer. Kaplan-Meier curves revealed that higher expression of DNAJB11 was significantly associated with poor disease-free survival and overall survival.Multivariate survival analysis revealed that strong positive expression of DNAJB11 was an independent prognostic factor for disease-free survival and overall survival. Conclusion: DNAJB11 may play a role in tumorigenesis and progression of epithelial ovarian cancer.Strong positive expression of DNAJB11 was an independent prognostic factor in epithelial ovarian cancer.
|
Received: 30 September 2016
Published: 31 October 2017
|
Corresponding Authors:
LV Weiguo
E-mail: 110790470@qq.com;lbwg@zju.edu.cn
|
卵巢上皮性癌组织中DNAJB11的表达及临床意义
目的:探讨DNAJB11蛋白在卵巢上皮性癌组织中表达及其临床价值。方法:采用免疫组织化学EnVision法检测105份卵巢上皮性癌的石蜡包埋组织DNAJB11蛋白的表达情况,并与23份正常卵巢组织、17份卵巢良性肿瘤组织、13份卵巢交界性肿瘤组织对比,用χ2检验分析其与临床病理特征的关系,用Kaplan-Meier法及COX比例风险回归模型分析其与患者生存预后的关系。结果:DNAJB11蛋白在正常卵巢组织及卵巢良性肿瘤中几乎不表达,在交界性肿瘤组织中阳性率为7.7%,在卵巢上皮性癌组织中阳性率为78.1%,卵巢上皮性癌组织中DNAJB11表达均高于其余各卵巢病变和正常卵巢组织(均P<0.01)。在细胞分化程度为G2~G3、临床分期为Ⅲ~Ⅳ期、组织学类型为浆液性、术前外周血CA125水平大于500 IU/L的卵巢上皮性癌患者中,卵巢上皮组织DNAJB11蛋白表达均高于细胞分化程度为G1、临床分期为Ⅰ~Ⅱ期、组织学类型为非浆液性癌和血CA125水平不超过500 IU/L的患者(均P<0.05)。Kaplan-Meier生存曲线显示,DNAJB11强阳性表达与上皮性卵巢癌患者的总生存预后及无瘤生存预后相关(P<0.01);多因素分析结果显示,DNAJB11蛋白强阳性表达是卵巢上皮性癌无瘤生存及总生存的独立预后因素。结论:DNAJB11蛋白可能在卵巢上皮性癌发生发展过程中起重要作用;卵巢上皮组织DNAJB11蛋白强阳性表达是卵巢上皮性癌患者的独立预后因素。
关键词:
卵巢肿瘤/病理学,
蛋白质组学,
免疫组织化学,
预后
|
|
[1] |
沈 铿 , 马 丁 . 妇产科学, 3版 北京 人民卫生出版社 2015, 321- SHEN Keng , MA Ding . Obstetrics and Gynecology, 3rd Beijing People's Health Publishing House 2015, 321-
|
|
|
[2] |
LI Y L , YE F , CHENG X D et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer[J]. Eur J Cancer, 2010, 46 (11): 2104- 2118
doi: 10.1016/j.ejca.2010.04.015
|
|
|
[3] |
INNOCENZI D , ALò P L , BALZANI A et al. Fatty acid synthase expression in melanoma[J]. J Cutan Pathol, 2003, 30 (1): 23- 28
doi: 10.1034/j.1600-0560.2003.300104.x
|
|
|
[4] |
BEREK J S , CRUM C , FRIEDLANDER M . Cancer of the ovary, fallopian tube and peritoneum[J]. Int J Gynecol Obstet, 2015, 131 (Suppl 2): S111- S122
|
|
|
[5] |
YU M , HASLAM R H , HASLAM D B . HEDJ, an Hsp40 co-chaperone localized to the endoplasmic reticulum of human cells[J]. J Biol Chem, 2000, 275 (32): 24984- 24992
doi: 10.1074/jbc.M000739200
|
|
|
[6] |
OHTSUKA K , HATA M . Mammalian HSP40/DNAJ homologs: cloning of novel cDNAs and a proposal for their classification and nomenclature[J]. Cell Stress Chaperones, 2000, 5 (2): 98- 112
doi: 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2
|
|
|
[7] |
MASSEY S , BURRESS H , TAYLOR M et al. Structural and functional interactions between the cholera toxin A1 subunit and ERdj3/HEDJ, a chaperone of the endoplasmic reticulum[J]. Infect Immun, 2011, 79 (11): 4739- 4747
doi: 10.1128/IAI.05503-11
|
|
|
[8] |
MARCINOWSKI M , H?LLER M , FEIGE M J et al. Substrate discrimination of the chaperone BiP by autonomous and cochaperone-regulated conformational transitions[J]. Nat Struct Mol Biol, 2011, 18 (2): 150- 158
doi: 10.1038/nsmb.1970
|
|
|
[9] |
GUO F , SNAPP E L . ERdj3 regulates BiP occupancy in living cells[J]. J Cell Sci, 2013, 126 (Pt 6): 1429- 1439
|
|
|
[10] |
JIN Y , AWAD W , PETROVA K et al. Regulated release of ERdj3 from unfolded proteins by BiP[J]. EMBO J, 2008, 27 (21): 2873- 2882
doi: 10.1038/emboj.2008.207
|
|
|
[11] |
NAKANISHI K , KAMIGUCHI K , TORIGOE T et al. Localization and functionin endoplasmic reticulum stress tolerance of ERdj3, a new member of Hsp40 family protein[J]. Cell Stress Chaperones, 2004, 9 (3): 253- 264
doi: 10.1379/CSC-52.1
|
|
|
[12] |
BERNAL-BAYARD J , CARDENAL-MU?OZ E , RAMOS-MORALES F . The salmonella type Ⅲ secretion effector, salmonella leucine-rich repeat protein (SlrP), targets the human chaperone ERdj3[J]. J Biol Chem, 2010, 285 (21): 16360- 16368
doi: 10.1074/jbc.M110.100669
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|